Otsuka ICU Medical’s potassium chloride recall: What went wrong with Lot 1030613?

Otsuka ICU Medical LLC has initiated a voluntary nationwide recall of one lot of its 20 mEq Potassium Chloride Injection in the US due to a critical labeling error that may result in potentially life-threatening overdoses. The mislabeling issue involves an incorrect outer wrap that identifies the product as a 10 mEq dose, while the actual content remains a higher-strength 20 mEq dose. The affected lot was distributed across the United States between May 23 and August 26, 2025.

The recalled product, listed under National Drug Code (NDC) 0990-7077-14 and Lot 1030613, has a labeled expiration date of September 30, 2026. It was packaged in 50 mL flexible containers. However, due to a manufacturing error, the overwrap was mistakenly labeled with the NDC 0990-7074-26, which corresponds to a 10 mEq potassium chloride dose typically packaged in a 100 mL flexible container. This mislabeling means healthcare providers relying solely on the overwrap could inadvertently administer double the intended dose of potassium chloride.

How serious is the risk from the potassium chloride injection recall and who is affected most?

The error, although confined to packaging, has significant clinical implications due to the narrow therapeutic index of potassium chloride and its use in critical care. An overdose of potassium chloride can result in hyperkalemia—a dangerous increase in serum potassium levels—which may cause muscle weakness, ascending paralysis, mental confusion, hypotension, cardiac arrhythmias, or even cardiac arrest.

Patients most at risk include premature infants, individuals on chronic parenteral nutrition, patients with chronic or acute renal impairment, those taking potassium-sparing diuretics, and individuals with a history of cardiac arrhythmias. These groups are highly sensitive to potassium fluctuations, making accurate dosage labeling essential for safe administration.

Otsuka ICU Medical LLC confirmed that no adverse events have been reported related to this batch as of the recall date. However, healthcare providers have been urged to treat the recall with utmost urgency, especially in high-risk units like intensive care, oncology wards, and neonatal units, where potassium chloride is often administered under tight fluid volume restrictions.

What specific product batch has been recalled and what are the identifying details?

The batch in question was manufactured on April 15, 2025, and features the following key product identifiers:

NDC: 0990-7077-14

Lot Number: 1030613

Expiration Date: September 30, 2026

Product Description: Potassium Chloride Injection 20 mEq

Configuration: 50 mL in flexible container, packed 24 units per case

Incorrect Overwrap: Identifies as Potassium Chloride Injection 10 mEq, NDC 0990-7074-26

The issue was isolated to a single lot, with no impact reported on other lots or formulations. The actual 20 mEq dosage is correctly printed on the internal bag, but because the overwrap conceals it, clinical staff may unknowingly administer the product based on the incorrect 10 mEq labeling on the outside.

What steps are being taken to address the recall and inform affected institutions?

Otsuka ICU Medical LLC has formally notified the U.S. Food and Drug Administration (FDA) of the recall and has begun issuing direct letters to its customer base, including hospitals and distributors. The recall is being conducted at the user level, which means all healthcare providers who received this lot are required to halt usage immediately and initiate return procedures.

Customers who have the affected product should contact Sedgwick at 1-888-566-2363 between 8:00 a.m. and 5:00 p.m. Eastern Time to obtain a return shipping label. In addition, Otsuka ICU Medical LLC has provided a list of departmental contacts for different support functions, ranging from medical inquiries and drug safety to field action processing and customer service.

Healthcare providers have also been encouraged to report any suspected adverse events or quality issues directly to the FDA’s MedWatch Adverse Event Reporting system. This can be done online at www.fda.gov/medwatch or by downloading the MedWatch reporting form for mail or fax submission.

Why is potassium chloride labeling so critical in intensive care settings?

Potassium chloride is a high-alert medication used in hospitals for the correction of hypokalemia, especially when oral administration is not possible. Because of its concentration and the severe risks associated with dosing errors, it is one of the most tightly controlled injectable drugs in clinical protocols. Mistakes with potassium chloride—especially in intravenous form—can result in rapid onset of symptoms and are frequently associated with fatal outcomes when administered improperly.

Labeling accuracy becomes even more essential in intensive care units and surgical recovery areas, where high-alert medications are administered under pressure and often in urgent conditions. In such environments, providers depend on the accuracy of external packaging, and any deviation can bypass even the most rigorous verification systems.

Otsuka ICU Medical LLC has acknowledged that the error stems from a manufacturing process issue but did not elaborate on whether this was a packaging or supply chain oversight. However, the company emphasized that internal labeling on the product bags themselves remains accurate and unaffected.

What are the broader implications for hospital protocols and patient safety?

Even though no adverse outcomes have been recorded, this recall highlights the persistent challenges in pharmaceutical packaging and labeling—an area that remains prone to human and mechanical errors despite technological advancements. Hospitals may now consider revisiting their double-check protocols, such as verifying inner bag labeling for high-alert medications, especially potassium chloride.

The incident also underscores the need for hospitals to adopt comprehensive barcode scanning systems, electronic medication administration records (eMARs), and staff training on identifying mismatches between overwrap and inner labeling.

Analysts familiar with hospital purchasing systems noted that product recalls involving essential medications like potassium chloride can lead to temporary disruptions in clinical workflows. Inventory teams are likely to accelerate inspections of stockpiled injectable medications to prevent downstream use.

Otsuka ICU Medical LLC has signaled its intent to maintain transparency and has directed all future inquiries to its medical and customer service teams. The recall also reinforces the importance of robust quality checks at every step of drug manufacturing and packaging.

What should hospitals and clinicians do immediately after this potassium chloride recall?

Healthcare providers who have received products from Lot 1030613 should immediately isolate the inventory and refrain from administering any units. Return coordination should be initiated via the contact lines shared by Otsuka ICU Medical LLC. Pharmacy and nursing teams should also review protocols around labeling verification for all high-risk injectables.

Although no immediate adverse events have been reported, heightened awareness and proactive communication with clinical teams are vital to ensuring patient safety. As hospitals await further clarification from the manufacturer on corrective actions, temporary procedural safeguards should be enacted.

Otsuka ICU Medical LLC continues to work with regulatory agencies to monitor the situation and will provide updates as needed. Meanwhile, the recall serves as a critical reminder of the need for end-to-end quality control and real-time issue resolution in healthcare supply chains.

Key takeaways: What hospitals and clinicians need to know about the Otsuka ICU Medical potassium chloride recall

• Otsuka ICU Medical LLC has issued a voluntary nationwide recall for Lot 1030613 of Potassium Chloride Injection 20 mEq due to a mislabeling issue that could result in accidental overdosing.

• The overwrap label incorrectly identifies the 20 mEq dose as 10 mEq, potentially leading clinicians to administer double the intended dosage if relying solely on outer packaging.

• The correct 20 mEq dosage is printed on the inner bag, but is not visible when the mislabeled overwrap is in place, creating a serious clinical risk in high-pressure care environments.

• Patients most at risk include those with kidney conditions, cardiac arrhythmias, and premature infants, all of whom are highly vulnerable to potassium toxicity and hyperkalemia.

• No adverse events have been reported as of October 31, 2025, but Otsuka ICU Medical is urging immediate return and discontinuation of use for all affected products.

• The recall covers units distributed in the U.S. between May 23 and August 26, 2025, packaged in 50 mL flexible containers with an expiration date of September 30, 2026.

• Otsuka ICU Medical LLC has contacted the FDA and is actively coordinating returns through Sedgwick, providing full support for distributors, hospitals, and pharmacies.

• Hospitals are advised to review internal protocols for injectable high-alert medications, especially potassium chloride, and ensure proper labeling verification before administration.

• The incident reinforces the importance of manufacturing safeguards and multi-tier drug checks, especially for injectable medications used in critical care and fluid-restricted patients.